Table 3 |
|||
|
Frequencies of different cell populations in SLE patients and healthy controls |
|||
|
Cell population |
Healthy controls (median and 95% CI)1 |
SLE patients (median and 95% CI) |
P-value |
|
|
|||
|
CD3+ T cells |
60.9 (57.8 to 63.9) |
65.1 (55.7 to 64.3) |
0.42 |
|
CD4+ T cells |
62.1 (57.0 to 64.7) |
55.2 (51.3 to 58.9) |
0.06 |
|
CD4+HLA-DR+ |
6.5 (5.3 to 7.2) |
31.3 (24.9 to 36.9) |
0.001 |
|
CD8+ T cells |
15.7 (14.3 to 18.8) |
20.4 (18.6 to 24.0) |
0.02 |
|
CD8+HLA-DR+ |
40.8 (39.0 to 43.2) |
36.9 (33.4 to 41.5) |
0.33 |
|
BDCA-1+ mDCs |
0.40 (0.34 to 0.46) |
0.31 (0.28 to 0.62) |
0.19 |
|
BDCA-2+ pDCs |
0.07 (0.07 to 0.11) |
0.09 (0.09 to 0.16) |
0.39 |
|
CD14++CD16- monocytes |
10.1 (9.6 to 13.3) |
16.9 (16.0 to 25.2) |
0.013 |
|
CD14++CD16+ monocytes |
0.17 (0.15 to 0.27) |
0.30 (0.44 to 0.81) |
0.003 |
|
CD19+ B cells |
5.6 (4.7 to 6.3) |
5.1 (5.0 to 7.8) |
0.78 |
|
CD19+CD27+IgD-CD38+CD20- |
0.43 (0.35 to 0.75) |
1.0 (0.8 to 3.0) |
< 0.0001 |
|
|
|||
|
1For CD3+ T cells, dendritic cells, monocytes and B cells the percentage is calculated against the total leukocyte count. For all subpopulations, the percentage is calculated against the main population (for example, CD4+ T cells for all CD4+ T cell analyses). CI, confidence interval; HLA, human leukocyte antigen; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell |
|||
|
Lood et al. Arthritis Research & Therapy 2011 13:R60 doi:10.1186/ar3314 |
|||
